What do systematic reviews say?

Dornase alfa vs mannitol

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.02
  231 participants
  Low

Dornase alfa vs mannitol

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  231 participants
  Low

Dornase alfa vs mannitol

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 10.61 [0.27, 20.95]
  231 participants
  Low

Dornase alfa vs mannitol

Dornase alfa showed no clear difference in number of people experiencing exacerbations ‐ at 3 months compared with mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  RR 1.1 [0.25, 4.84]
  231 participants
  Low

Dornase alfa vs dornase alfa and mannitol

Dornase alfa showed no clear difference in mean absolute change in FEV1 (L) at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.1
  231 participants
  Low

Dornase alfa vs dornase alfa and mannitol

Dornase alfa showed no clear difference in mean absolute change in FVC (L) at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 0.13
  231 participants
  Low

Dornase alfa vs dornase alfa and mannitol

Dornase alfa may leads to higher change in quality of life ‐ CFQ‐R at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  MD 10.61 [0.27, 20.95]
  231 participants
  Low

Dornase alfa vs dornase alfa and mannitol

Dornase alfa showed no clear difference in number of people experiencing exacerbations at 3 months compared with dornase alfa and mannitol (low certainty).

• Dornase alfa for cystic fibrosis 2021 · Cochrane Headline outcomes only
  RR 0.55 [0.16, 1.92]
  231 participants
  Low

V6 chewing gum / mucin chewing gum vs PTC chewing gum (xylitol/sorbitol/mannitol)

• Interventions for the management of dry mouth: topical therapies 2011 · Cochrane All outcomes
  Olsson 1991 (crossover, high risk of bias, n=14): both gums increased saliva secretion, peaking 17.5 minutes after chewing started; significant treatment-by-period interaction; no per-group data presented.
  1 study · 14 participants
  GRADE not reported

Intervention not reported

The intervention may leads to lower death (low certainty).

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  RR 0.81
  1 study · 156 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 156 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The review found no eligible studies for this question.

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Mannitol and other osmotic diuretics as adjuncts for treating cerebral malaria 2011 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 156 participants
  Low